CYP2D6
目录号 : GP21536Cytochrome P450 2D6 Human Recombinant (also called liver/kidney microsomal antigen 1) produced in SF9, is a glycosylated, polypeptide chain having a molecular mass of 60 kDa.
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Cytochrome P450 2D6 Human Recombinant (also called liver/kidney microsomal antigen 1) produced in SF9, is a glycosylated, polypeptide chain having a molecular mass of 60 kDa. The LKM1 is purified by proprietary chromatographic techniques.
Cytochrome P450 2D6 is a member of a complex family of microsomal enzymes (mono-oxygenases) present in the endoplasmic reticulum membrane, which perform detoxification reaction on xenobiotic compounds. Cytochrome P450 2D6 is the molecular target of autoantibodies against the "liver kidney microsomal antigen 1" (LKM 1) which has been classically defined by immunofluorescence microscopy. The presence of these autoantibodies is considered indicative of Autoimmune Hepatitis Type 2; LKM 1 antibodies have also been detected in patients with hepatitis C viral infection. The International Autoimmune Hepatitis Group therefore has subdivided the AIH type 2 into two subgroups: 2a with HCV and 2b without HCV. AIH 2a patients are often over 40 and predominantly male.
The use of a purified recombinant Cytochrome P450 2D6 antigen allows the differentiation of autoimmune hepatitis from drug-induced hepatitis where transient autoantibodies to other P450 family members occur which cannot be differentiated by immunofluorescence techniques.
| Purity | Greater than 95% as determined by SDS-PAGE. | Source | Sf9 insect cells. |
| Phycical Appearance | Sterile filtered liquid formulation. | Shipping Condition | Shipped with Ice Packs. |
| Synonyms | Cytochrome P450 2D6; CYPIID6; P450-DB1; Debrisoquine 4-hydroxylase; CYP2D6; CPD6; CYP2D; CYP2D@; CYP2DL1; P450C2D; MGC120389; MGC120390; LKM1; liver/kidney microsomal antigen 1. | ||
| Stability | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles. | ||
| Formulation | LKM-1 is supplied in 17mM HEPES pH-7.5, 425mM NaCl, 1mM DTT, 1% Triton X-100 and 15% glycerol. | ||
Cytochrome P450 2D6 Human Recombinant (also called liver/kidney microsomal antigen 1) produced in SF9, is a glycosylated, polypeptide chain having a molecular mass of 60 kDa. The LKM1 is purified by proprietary chromatographic techniques. Cytochrome P450 2D6 is a member of a complex family of microsomal enzymes (mono-oxygenases) present in the endoplasmic reticulum membrane, which perform detoxification reaction on xenobiotic compounds. Cytochrome P450 2D6 is the molecular target of autoantibodies against the "liver kidney microsomal antigen 1" (LKM 1) which has been classically defined by immunofluorescence microscopy. The presence of these autoantibodies is considered indicative of Autoimmune Hepatitis Type 2; LKM 1 antibodies have also been detected in patients with hepatitis C viral infection. The International Autoimmune Hepatitis Group therefore has subdivided the AIH type 2 into two subgroups: 2a with HCV and 2b without HCV. AIH 2a patients are often over 40 and predominantly male. The use of a purified recombinant Cytochrome P450 2D6 antigen allows the differentiation of autoimmune hepatitis from drug-induced hepatitis where transient autoantibodies to other P450 family members occur which cannot be differentiated by immunofluorescence techniques.
Western-Blot with monoclonal anti-LKM-1 antibody and anti-LKM-1 autoantibody- positive sample.
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles.